Effect of a Single Intravitreal Ranibizumab Injection on Diabetic Macular Edema in Patients Who Discontinued Treatment
Erhan Yumusak 1 * , Murat Kücükevcilioglu, Kemal Ornek, Nesrin Büyüktortop
More Detail
1 Kırıkkale Universitesi Tıp Fakültesi Hastanesi, Kırıkkale, Turkey
* Corresponding Author

Abstract

Objective: To evaluate the effect of a single dose of ranibizumab in patients with diabetic macular edema who discon­tinued treatment.
Methods: One eye of 85 patients with diabetic macular edema who discontinued treatment after a single injection of ranibizumab was studied. Best corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT), and optical coherence tomography imaging were evaluated retrospectively. Changes in BCVA, IOP, CMT, and their correlations with the follow-up period were statistically analyzed.
Results: At baseline, the mean BCVA was 0.26 ± 0.20 (Snellen equivalent [SE]) and CMT was 469.04 ± 144.6 μm. After a mean period of 6.12 ± 2.46 months, mean BCVA was 0.316 ± 0.23 SE and CMT was 403.07± 139.7 μm. There was a statistically significant increase in BCVA and decreased in CMT (p= 0.02, p< 0.01, respectively), whereas mean IOP values did not significantly change (p=0.24). There was no statistically significant correlation between the follow-up duration and BCVA or CMT (p=0.928 and p=0.992, respectively).
Conclusions: Visual outcome and CMT thickness were still superior to those before treatment even after a single ranibi­zumab injection.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

https://doi.org/10.5799/ahinjs.01.2016.02.0595

J Clin Exp Invest, 2016 - Volume 7 Issue 2, pp. 190-194

Publication date: 16 Jun 2016

Article Views: 1733

Article Downloads: 371

Open Access References How to cite this article